Armata Pharmaceuticals (ARMP) Research & Development (2013 - 2026)

Armata Pharmaceuticals has disclosed Research & Development across 14 years of filings, most recently posting $6.1 million for Q1 2026.

• Research & Development for Q1 2026 came in at $6.1 million, up 12.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.4 million (down 23.37% YoY), and the FY2025 annual result was $23.7 million, down 31.11% from the prior year.
• Research & Development came in at $6.1 million for Q1 2026 at Armata Pharmaceuticals, up from $6.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $9.6 million in Q1 2023 to a low of $5.4 million in Q1 2025.
• The 5-year median for Research & Development is $8.0 million (2022), against an average of $7.8 million.
• Across the five-year window, Research & Development jumped 98.77% in 2022 and slumped 38.6% in 2025, its largest moves.
• Armata Pharmaceuticals' Research & Development stood at $9.6 million in 2022, then slipped by 17.15% to $7.9 million in 2023, then gained by 6.6% to $8.5 million in 2024, then dropped by 28.17% to $6.1 million in 2025, then gained by 0.68% to $6.1 million in 2026.
• The last three Research & Development figures came in at $6.1 million (Q1 2026), $6.1 million (Q4 2025), and $5.8 million (Q3 2025), per Business Quant data.